These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32472047)

  • 1. Evaluation of ocular surface disease in elderly patients with glaucoma: expression of matrix metalloproteinase-9 in tears.
    Kim DW; Seo JH; Lim SH
    Eye (Lond); 2021 Mar; 35(3):892-900. PubMed ID: 32472047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma.
    Zaleska-Żmijewska A; Strzemecka E; Wawrzyniak ZM; Szaflik JP
    J Ophthalmol; 2019; 2019():1240537. PubMed ID: 31073413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay.
    Messmer EM; von Lindenfels V; Garbe A; Kampik A
    Ophthalmology; 2016 Nov; 123(11):2300-2308. PubMed ID: 27665213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular surface disease incidence in patients with open-angle glaucoma.
    Radenković M; Stanković-Babić G; Jovanović P; Djordjević-Jocić J; Trenkić-Božinović M
    Srp Arh Celok Lek; 2016; 144(7-8):376-83. PubMed ID: 29652117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular surface changes in primary open-angle glaucoma on anti-glaucoma medications versus treatment-naïve patients.
    Srivastava K; Bhatnagar KR; Shakrawal J; Tandon M; Jaisingh K; Pandey L; Roy F
    Indian J Ophthalmol; 2024 Mar; 72(3):374-380. PubMed ID: 38099355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the histopathology and matrix metalloproteinase expression in Tenon's tissue of primary open-angle glaucoma and primary angle-closure glaucoma.
    Seo JH; Park KH; Kim YJ; Yoo YC; Kang SH; Kim DM
    Korean J Ophthalmol; 2008 Mar; 22(1):37-42. PubMed ID: 18323704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of point-of-care test for elevated tear matrix metalloproteinase 9 in post-LASIK dry eyes.
    Chan TC; Ye C; Chan KP; Chu KO; Jhanji V
    Br J Ophthalmol; 2016 Sep; 100(9):1188-91. PubMed ID: 26682569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.
    Saade CE; Lari HB; Berezina TL; Fechtner RD; Khouri AS
    Can J Ophthalmol; 2015 Apr; 50(2):132-6. PubMed ID: 25863853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients.
    Schargus M; Ivanova S; Kakkassery V; Dick HB; Joachim S
    Cornea; 2015 Jul; 34(7):739-44. PubMed ID: 25909238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Ramadan daytime fasting with ocular surface inflammation and dry eye.
    Armstrong BK; Coc IR; Agarwal P; Smith S; Navon S
    Int Ophthalmol; 2019 Dec; 39(12):2857-2863. PubMed ID: 31152289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding Ocular Surface Disease in Glaucoma: A Comparative Analysis of Symptoms and Objective Parameters.
    Romano J; Ferreira N; Godinho G; Tomás R; Oliveira N; Sousa JP
    Cureus; 2024 Feb; 16(2):e54070. PubMed ID: 38481920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
    Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
    Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A preliminary study on the tear matrix metalloproteinase 9 point-of-care assay using a domestic kit].
    Wan XC; Zhang H; Shen Y; Zhou SY; Yang P; Zhou XJ; Gu H; Le QH; Xu JJ; Zhou XT; Hong JX
    Zhonghua Yan Ke Za Zhi; 2023 Apr; 59(4):272-278. PubMed ID: 37012590
    [No Abstract]   [Full Text] [Related]  

  • 16. Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease.
    Park JY; Kim BG; Kim JS; Hwang JH
    Transl Vis Sci Technol; 2018 Sep; 7(5):31. PubMed ID: 30386683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of ocular surface disease in glaucoma patients.
    Leung EW; Medeiros FA; Weinreb RN
    J Glaucoma; 2008 Aug; 17(5):350-5. PubMed ID: 18703943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases.
    Dubrulle P; Labbé A; Brasnu E; Liang H; Hamard P; Meziani L; Baudouin C
    J Glaucoma; 2018 Dec; 27(12):1105-1111. PubMed ID: 30489502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tear matrix metalloproteinase-9 levels may help to follow a ocular surface injury in lagophthalmic eyes.
    Minaříková M; Fík Z; Štorm J; Helisová K; Ferrová K; Mahelková G
    PLoS One; 2022; 17(9):e0274173. PubMed ID: 36084126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry eye disease among Glaucoma patients on topical hypotensive medications, in a tertiary hospital, Ethiopia.
    Sahlu M; Giorgis AT
    BMC Ophthalmol; 2021 Mar; 21(1):155. PubMed ID: 33785013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.